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Long-Term Protection from Bovine Viral Diarrhea Virus 
A in Feedlot Cattle 
C.C.L. Chase,' J. Hans~n,~ T. Fra~er,~ L.Bra~n,~ S. Ander~on,~ and D.J. Hurley 
Departments of Veterinary Science and Biology/Microbiology 
SDSU CAl lLE 96-9 
Summary 
Bovine viral diarrhea virus (BVDV) causes 
respiratory and reproductive disease. The 
duration of immunity of an inactivated vaccine 
(Virashield 5: Grand Laboratories, Freeman, SD) 
was measured in t w o  challenge studies. In both 
studies the vaccinated animals demonstrated 
fewer clinical signs when challenged wi th  Type 
II BVDV at 11  or 1 3  months post vaccination. 
These results indicate that an inactivated 
vaccine administered properly can protect 
animals against disease up to  at least a year 
post vaccination. 
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BVDV vaccines have traditionally been 
either modified live virus (MLV) or inactivated 
viruses. MLV vaccines have been touted on 
their ability t o  produce cell immunity and to  
have a longer duration of action. 
This study was designed t o  assess the 
efficacy and duration of cattle vaccinated wi th  
the inactivated Virashield 5 (Grand Laboratories, 
Freeman, SD) by challenging the animals w i th  
BVDV. This report details the results of these 
clinical trials. 
Materials and Methods 
Animals 
Trial 1 
Introduction 
Bovine viral diarrhea virus (BVDV) has 
emerged as the major viral disease of cattle. 
BVDV is the predominant virus isolated from 
bovine respiratory disease (BRD) and from 
abortions at the Animal Disease Research and 
Diagnostic Laboratory at South Dakota State 
University. BVDV was isolated from 100  
submissions and represented 89% of all BRD 
viral isolations made in 1995. Two  biotypes of 
BVDV virus have been recognized. Type I BVDV 
is the major type that has been responsible for 
most clinical BVDV in South Dakota. Type II 
BVDV has emerged in several areas of the 
country and has been implicated in acute BVDV 
outbreaks. 
Vaccinates. Six crossbred calves (Charolais 
cross, 500-750 Ib) seronegative for BVDV were 
vaccinated in June 1994 wi th  5 m l  of 
Virashield 5 intramuscular. A second dose was 
administered 1 month later. 
Control. Three crossbred calves (Charolais 
cross, 400-500 Ib) seronegative for IBR, BVDV, 
and BRSV were used as controls. 
Trial 2 
Vaccinates. Six yearling calves (Holstein 
cross, 1 100-1 200  Ib) seronegative for BVDV 
were vaccinated in October of 1994. The 
animals were injected wi th  5 ml  of Virashield 5 
intramuscular. A second dose was administered 
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one month later. In November 1995, the 
animals were moved t o  the Department of 
Veterinary Science, South Dakota State 
University. 
Control. Three yearling calves (Holstein 
cross, 1 100-1 200 Ib) seronegative for BVDV 
were used as controls. 
Challenge 
m. The BVDV challenge virus was from 
the National Veterinary Service Laboratory, 
Ames, IA. The challenge vials were labeled 
"NVSL BVD Challenge Virus (890) Lot# 94-9. 
The challenge upon dilution with 2.8 ml of 
diluent was lo7.' tissue culture infectious dose 
50 (TCID 50:the amount of virus required to  kill 
50% of the cells) per animal. 
Virus Inoculation 
beginning 3 days prior to  challenge and 
continued until 14  days post infection. 
Statistical analysis was done using a student 
T-test with significance cutoff of 0.05. 
Clinical Diarrhea Sians-BVDV. Fecal 
consistency was measured beginning 3 days 
prior to challenge and continued until 1 4  days 
post infection in the BVDV challenge. The 
scoring system was 0 = normal consistency; 1 
= loose consistency, and 2 = watery 
consistency. Statistical analysis was done using 
a student T-test with significance cutoff of 
0.05. 
Seroloau. Blood samples were drawn from 
all animals in each challenge. The samples were 
drawn prior to  infection and at -2, 5, 12, and 
26 days post infection. Serum was harvested 
and stored at -70" C. The serum was shipped 
to Grand Laboratories, Larchwood, IA, for serum 
neutralization testing. 
Trial 1 
-
Results and Discussion 
Nine animals were challenged 11 months 
following the first vaccination with the BVDV 
virus inoculum described above. Each calf was 
swabbed prior to  challenge, 2 ml per nostril 
( 4  ml total) of inoculum was administered with 
an atomizer in each nostril and the calves were 
swabbed for virus isolation post inoculation. 
Trial 2 
-
Nine animals were challenged 13  months 
following the first vaccination with the BVDV 
virus inoculum described above. Each calf was 
swabbed prior to  challenge, 2 ml per nostril 
( 4  ml total) of inoculum was administered with 
an atomizer in each nostril, and the calves were 
swabbed for virus isolation post inoculation 
Testing Procedures 
Clinical Res~iratorv Sians and 
Tem~erature. During each challenge, animals 
were observed daily for clinical signs beginning 
3 days prior to  challenge and continued until 
14  days post challenge. The animals were 
observed for lacrimation, conjunctivitis, 
dyspnea, and nasal discharge and clinical scores 
assigned. The basal body temperature was also 
measured rectally with a digital thermometer 
BVDV Clinical Res~iratory Scores (includes body 
temperature) 
Trial 1. Prior to challenge, all the cattle had 
-- 
a mild serous nasal discharge. At day 7 post 
infection, there was a threefold increase over 
pre-challenge scores in the control animals. This 
continued out to  day 13  post infection. There 
was a significant increase (P< .05) in clinical 
scores between the two  groups on days 8 to  13 
of the BVDV experiment (Figure 1). 
Trial 2. Prior to challenge, all the cattle had 
a mild serous nasal discharge. There was no 
difference in the clinical signs between the two  
groups. On days 7 and 8 post challenge, the 
controls had higher scores, but there was no 
clear trend. The body temperatures in these 
groups did not vary much. On days 8 and 9, 
the controls had temperatures 2 "  higher than 
the vaccinates (data not shown). 
Clinical Diarrhea Scores BVDV 
Trial 1. Fecal consistency was similar for 
both groups prior to  challenge and up to  day 7 
post infection (Figure 2). On days 8, 10, and 
11, there was a significant increase (P< .05) in 
diarrhea in  the control animals (Figure 2). 
Trial 2. There was no difference in fecal 
scores between the t w o  groups (data not 
shown). 
Seroloav 
. Vaccinated animals developed 
BVDV serum titers that peaked 2 to  3 months 
following the first vaccination (Figure 3). 
Figure 3 is representative of the serological 
response in  Trial 1 against either Type I or 
Type II BVDV. Following infection, the serum 
titers of  the vaccinated animals reached very 
high levels compared to  the controls. 
representative of the serological response in 
Trial 2 against either Type I or Type II BVDV. 
These results indicate that vaccination w i th  
a properly administered inactivated vaccine can 
result in protection of feeder cattle from 
challenge wi th BVDV Type II over a year after 
vaccination. Respiratory disease in feedlot 
cattle continues t o  be a serious problem in the 
cattle industry. One of the important questions 
yet t o  be answered concerns the protection of 
cows against fetal BVDV infection. This 
infection results in abortions and BVDV 
persistently infected calves in the herd. These 
persistently infected animals maintain the virus 
in  the herd and are a threat t o  even well 
vaccinated animals. Future studies are planned 
t o  answer these questions. 
Trial 2. The serological response was 
-
similar t o  Trial 1 (Figure 4). Figure 4 is 
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Figure 1. Bovine Viral Diarrhea Virus Clinical Scores 
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Figure 2. Diarrheal Scores following BVDV lnfection 
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Figure 3. BVDV-Trial 1 Serum Neutralization Titers 
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Figure 4. BVDV-Trial 2 Serum Neutralization Titers 
